Print



Simvastatin (Flolipid®, Zocor®)

Simvastatin (Flolipid®, Zocor®) belongs to a class of medications called statins. It is used to lower cholesterol levels and to reduce the risk for heart attack, stroke, and other heart problems.

Jamie, based on your genetic result, your body is likely to have a typical response to simvastatin (Flolipid®, Zocor®). This means that based on the DNA variant we tested, simvastatin (Flolipid®, Zocor®) is likely to work as

expected for you. However, other factors – such as having a DNA variant not included in this test, certain health conditions, or taking other medications - may influence your response. Do not use this result to start, stop, or change any course of treatment. Medications should always be taken as directed.




to simvastatin (Flolipid®, Zocor®)

Likely typical response




Learn more about your result

Keep in mind




medication, continue your

treatment as directed unless your doctor recommends a change.




body's response to this medication.



MIM

may affect your body's response to this medication.



medications.


About simvastatin

Also known as: Flolipid®¹, Zocor®²; and in combination products known as Simcor®³ and Vytorin®⁴



along with diet to reduce bad cholesterol (low-density lipoprotein

cholesterol, LDL-C) in adults with hyperlipidemia and in adults and children aged 10 years and older with a genetic condition called heterozygous familial hypercholesterolemia. It is used in adults with primary dysbetalipoproteinemia (a condition that causes high levels of cholesterol and fat in the blood), hypertriglyceridemia, and homozygous familial hypercholesterolemia. It is used to reduce the risk of heart attack, stroke, certain types of heart and blood vessel surgery, and death from heart disease in adults with heart disease or at high risk of developing heart disease. Read more at: **MedlinePlus' DailyMed'**



help prevent cholesterol from building up on the walls of blood


vessels, which can help reduce the risk of heart attack and stroke.

If you ever need treatment with simvastatin, a healthcare professional like your doctor or pharmacist may be able to use this report for reference. Do not use this result to start, stop, or change any course of treatment.

Share a summary of your Pharmacogenetics

reports with a healthcare professional.

Medications should always be taken as directed.



Predicted normal function

datalink." Clin Pharmacol Ther. 94(6):695-701.

primary care patients." J Pers Med. 4(2):147-62.

induced myopathy." Pharmacogenomics J. 21(3):296-307.

devices/precision-medicine/table-pharmacogenetic-associations

20. Ward NC et al. (2019). "Statin Toxicity." Circ Res. 124(2):328-350.

Date

from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206679s003lbl.pdf \


Implementation Consortium (CPIC)." Genet Med. 19(2):215-223.

2 diabetes: A go-DARTS study." Clin Pharmacol Ther. 89(2):210-6.

Statin-Associated Musculoskeletal Symptoms." Clin Pharmacol Ther. 111(5):1007-1021.

SLCO1B1 Drug Transport

Your Genetic Result



3. Cooper-DeHoff RM et al. (2022). "The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and

1. Carr DF et al. (2013). "SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research

2. Caudle KE et al. (2017). "Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics

4. Danik JS et al. (2013). "Lack of association between SLCO1B1 polymorphisms and clinical myalgia following rosuvastatin therapy." Am Heart J. 165(6):1008-14.

5. Donnelly LA et al. (2011). "Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type

6. Hopewell JC et al. (2020). "Independent risk factors for simvastatin-related myopathy and relevance to different types of muscle symptom." Eur Heart J. 41(35):3336-3342.

7. Li JH et al. (2014). "Genetically guided statin therapy on statin perceptions, adherence, and cholesterol lowering: a pilot implementation study in

8. Nielsen SF et al. (2016). "Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study." Eur Heart J. 37(11):908-916.

9. Pasanen MK et al. (2006). "SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid." Pharmacogenet Genomics. 16(12):873-9.

- 10. Peyser B et al. (2018). "Effects of delivering SLCO1B1 pharmacogenetic information in randomized trial and observational settings." Circ Genom Precis Med. 11(9):e002228. \
- 11. Pittman DG et al. (2011). "Adherence to statins, subsequent healthcare costs, and cardiovascular hospitalizations." Am J Cardiol. 107(11):1662-6. 12. SEARCH Collaborative Group et al. (2008). "SLCO1B1 variants and statin-induced myopathy--a genomewide study." N Engl J Med. 359(8):789-99.

13. Turongkaravee S et al. (2021). "A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-

14. Turner RM et al. (2020). "A genome-wide association study of circulating levels of atorvastatin and its major metabolites." Clin Pharmacol Ther. 108(2):287-97.

15. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "Flolipid® (simvastatin) NDA 206679 label." Retrieved August 30, 2021

- 16. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. "Zocor® (simvastatin) NDA 019766 label." Retrieved August 12, 2021 from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/019766s101lbl.pdf \
- 18. Vassy JL et al. (2020). "Effect of Pharmacogenetic Testing for Statin Myopathy Risk vs Usual Care on Blood Cholesterol: A Randomized Clinical Trial." JAMA Netw Open. 3(12):e2027092. \

19. Voora D et al. (2009). "The SLCO1B1*5 genetic variant is associated with statin-induced side effects." J Am Coll Cardiol. 54(17):1609-16.

17. U.S. Food and Drug Administration (2021). "Table of Pharmacogenetic Associations." Retrieved February 24, 2023 from https://www.fda.gov/medical-

Change Log

Your report may occasionally be updated based on new information. This Change Log describes updates and

revisions to this report.

Simvastatin (Flolipid®, Zocor®) report created. July 19, 2023

Change

¹Flolipid® is a registered trademark of Salerno Pharmaceuticals LP; ²Zocor® is a registered trademark of Merck & Co., Inc.; ³Simcor® is a registered trademark of Kos Pharmaceuticals, Inc.; 4Vytorin® is a registered trademark of MSP Singapore Company, LLC



Get \$20

Earn up to \$20 for each friend you refer.

All Ancestry Reports **Ancestry Composition DNA Relatives** Order Your DNA Book

ANCESTRY

Ancestry Overview

All Health & Traits Reports My Health Action Plan **Health Predisposition** Pharmacogenetics **Carrier Status**

Wellness


HEALTH & TRAITS

Health & Traits Overview

RESEARCH

Research Overview

Surveys and Studies Family Tree **Edit Answers** Your Connections **Publications** GrandTree Advanced DNA Comparison



FAMILY & FRIENDS

View all DNA Relatives





Traits ©2023 23andMe, Inc. Terms of Service Membership Terms Privacy Statement Cookie Policy Help Resources